A Phase 2 interventional study of PF-06700841 and Vehicle (Placebo) in Psoriasis, sponsored by Pfizer. Completed at 79 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.
Among the 57 studies in Psoriasis by Pfizer, this one is the 12th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 in phase 2, and was the 53rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 344 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 42 interventional studies, 458 across the 15 observational. Of the 56 that completed or were terminated, 46 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Psoriasis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vehicle cream applied once daily (QD)
Drug: Vehicle (Placebo)
PF-06700841 0.1% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 0.3% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 1% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 3% cream applied once daily (QD)
Drug: PF-06700841
PF-06700841 0.3% cream applied twice daily (BID)
Drug: PF-06700841
PF-06700841 1% cream applied twice daily (BID)
Drug: PF-06700841
Vehicle cream applied twice daily (BID)
Drug: Vehicle (Placebo)
PF-06700841 3% cream applied twice daily (BID)
Drug: PF-06700841
PF-06700841 topical cream
Vehicle topical cream
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
The Psoriasis Area and Severity Index (PASI) score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected body surface area (BSA) from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 12
Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12
PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.
Time frame: Baseline, Week 12
Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Change From Baseline in PASI Scores at Week 14 and 16
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 14 and 16
Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Percent Change From Baseline in PASI Scores at Week 14 and 16
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 14 and 16
Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Absolute PP-NRS Score at Week 14 and 16
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Week 14 and 16
Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Change From Baseline in PP-NRS Score at Week 14 and 16
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Baseline, Week 14 and 16
Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)
Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)
Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16
PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 14, and 16
Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
Time frame: Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With TEAEs by Severity
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event).
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants Who Discontinued From Study Due to Adverse Events
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Laboratory Abnormalities Meeting Specified Criteria
Bilirubin: greater than (\>) 1.5\* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: \>2.5\*ULN; creatinine, cystatin C: \>1.3\*ULN; creatine kinase: \>2.0\*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (\<) 60 milliliter (mL)/minute (min)/1.73 meter(m)\^2, greater than or equal to (\>=) 30% decrease from baseline; GFR: \<60 mL/min/1.73m\^2.
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data
Following were ECG criteria used for categorical summary:1) PR interval: percentage change \>=25/50%, QRS interval: value \>140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec \< value less than equal to (\<=) 480 and 30 \< change \<=60.
Time frame: Post-baseline to Week 6, Post-baseline to Week 12
Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
Following were the vital signs criteria: 1) Pulse rate: value \<40 beats per min (bpm), value \>120 bpm; 2) Sitting diastolic blood pressure (DBP): value \<50 mmHg; change \>=20 mmHg increase; change \>=20 mmHg decrease; 3) Sitting systolic blood pressure (SBP): value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease; 4) Supine DBP: value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; 5) Supine SBP: value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease.
Time frame: Post-baseline to Week 12
Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16
At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]).
Time frame: Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16
| Milestone | Stage 1: Vehicle Once Daily (QD) | Stage 1: PF-06700841 0.1% QD | Stage 1: PF-06700841 0.3% QD | Stage 1: PF-06700841 1.0% QD | Stage 1: PF-06700841 3.0% QD | Stage 1: Vehicle Twice Daily (BID) | Stage 1: PF-06700841 0.3% BID | Stage 1: PF-06700841 1.0% BID | Stage 2: Vehicle BID | Stage 2: PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 37 | 37 | 37 | 36 | 37 | 38 | 36 | 36 | 0 | 0 |
| Treated | 37 | 37 | 37 | 36 | 37 | 37 | 36 | 36 | 0 | 0 |
| Completed | 29 | 29 | 26 | 30 | 28 | 27 | 25 | 30 | 0 | 0 |
| Not completed | 8 | 8 | 11 | 6 | 9 | 11 | 11 | 6 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 3 | 0 | 2 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 | 2 | 2 | 2 | 1 | 2 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 2 | 3 | 2 | 4 | 3 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further treatment | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: Vehicle Once Daily (QD) | Stage 1: PF-06700841 0.1% QD | Stage 1: PF-06700841 0.3% QD | Stage 1: PF-06700841 1.0% QD | Stage 1: PF-06700841 3.0% QD | Stage 1: Vehicle Twice Daily (BID) | Stage 1: PF-06700841 0.3% BID | Stage 1: PF-06700841 1.0% BID | Stage 2: Vehicle BID | Stage 2: PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 37 | 37 | 37 | 36 | 37 | 37 | 36 | 36 | 0 | 0 |
| Completed | 37 | 34 | 35 | 34 | 34 | 33 | 34 | 33 | 0 | 0 |
| Not completed | 0 | 3 | 2 | 2 | 3 | 4 | 2 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further study procedures | 0 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: Vehicle Once Daily (QD) | Stage 1: PF-06700841 0.1% QD | Stage 1: PF-06700841 0.3% QD | Stage 1: PF-06700841 1.0% QD | Stage 1: PF-06700841 3.0% QD | Stage 1: Vehicle Twice Daily (BID) | Stage 1: PF-06700841 0.3% BID | Stage 1: PF-06700841 1.0% BID | Stage 2: Vehicle BID | Stage 2: PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 38 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 27 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 11 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Refused further treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Stage 1: Vehicle Once Daily (QD) | Stage 1: PF-06700841 0.1% QD | Stage 1: PF-06700841 0.3% QD | Stage 1: PF-06700841 1.0% QD | Stage 1: PF-06700841 3.0% QD | Stage 1: Vehicle Twice Daily (BID) | Stage 1: PF-06700841 0.3% BID | Stage 1: PF-06700841 1.0% BID | Stage 2: Vehicle BID | Stage 2: PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 38 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 36 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The Psoriasis Area and Severity Index (PASI) score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected body surface area (BSA) from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -1.6 ± 0.46 | -2.2 ± 0.46 | -1.4 ± 0.46 | -2.2 ± 0.46 | -2.4 ± 0.45 | -2.2 ± 0.42 | -2.5 ± 0.53 | -3.0 ± 0.51 | -2.8 ± 0.48 |
PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.
| Percentage of participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 6.9 (1.8 to 20.0) | 10.3 (3.9 to 22.9) | 15.4 (6.9 to 29.9) | 10.3 (3.9 to 22.9) | 21.4 (9.8 to 36.6) | 14.7 (7.3 to 26.9) | 20.8 (10.5 to 37.0) | 27.6 (14.5 to 42.5) | 17.9 (8.9 to 33.3) |
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
| Percentage of participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | 3.1 (0.3 to 13.1) | 3.0 (0.3 to 12.7) | 0 (0.0 to 8.0) | 0 (0.0 to 7.7) | 0 (0.0 to 7.7) | 0 (0.0 to 6.0) | 0 (0.0 to 8.5) | 2.9 (0.3 to 12.3) | 2.7 (0.3 to 11.2) |
| Week 2 | 3.1 (0.3 to 13.1) | 0 (0.0 to 7.5) | 0 (0.0 to 8.8) | 2.9 (0.3 to 11.9) | 0 (0.0 to 7.7) | 2.2 (0.2 to 9.2) | 0 (0.0 to 7.7) | 6.3 (1.7 to 18.0) | 5.7 (1.5 to 16.4) |
| week 4 | 3.1 (0.3 to 13.1) | 0 (0.0 to 8.5) | 3.6 (0.4 to 15.1) | 0 (0.0 to 8.0) | 0 (0.0 to 8.0) | 8.9 (3.9 to 18.0) | 6.7 (1.8 to 19.3) | 3.0 (0.3 to 12.7) | 12.1 (5.4 to 25.1) |
| Week 6 | 3.2 (0.3 to 13.5) | 0 (0.0 to 8.8) | 7.4 (2.0 to 20.4) | 6.5 (1.7 to 18.7) | 10.3 (3.9 to 22.9) | 13.9 (6.9 to 25.4) | 10.7 (4.0 to 23.8) | 10.7 (4.0 to 23.8) | 10.3 (3.9 to 22.9) |
| Week 8 | 6.7 (1.8 to 19.3) | 6.7 (1.8 to 19.3) | 7.4 (2.0 to 20.4) | 6.5 (1.7 to 18.7) | 14.3 (6.4 to 28.4) | 13.9 (6.9 to 25.4) | 16.0 (7.2 to 30.7) | 13.8 (6.2 to 27.9) | 14.3 (6.4 to 28.4) |
| Week 10 | 10.3 (3.9 to 22.9) | 3.3 (0.4 to 14.0) | 8.0 (2.1 to 21.4) | 17.2 (8.6 to 32.0) | 14.3 (6.4 to 28.4) | 18.2 (8.2 to 31.3) | 20.8 (10.5 to 37.0) | 10.7 (4.0 to 23.8) | 15.4 (6.9 to 29.9) |
| Week 12 | 10.3 (3.9 to 22.9) | 10.3 (3.9 to 22.9) | 7.7 (2.1 to 20.9) | 20.7 (9.4 to 35.2) | 17.9 (8.9 to 33.3) | 20.6 (11.3 to 34.9) | 12.5 (4.7 to 28.2) | 24.1 (13.4 to 38.5) | 17.9 (8.9 to 33.3) |
| Week 14 | 3.4 (0.4 to 14.5) | 7.7 (2.1 to 20.9) | 8.7 (2.3 to 22.8) | 21.4 (9.8 to 36.6) | 14.3 (6.4 to 28.4) | 10.3 (3.9 to 22.9) | 13.0 (4.9 to 29.6) | 20.0 (10.1 to 36.2) | 14.8 (6.6 to 29.1) |
| Week 16 | 3.4 (0.4 to 14.5) | 11.1 (4.2 to 24.8) | 17.4 (7.8 to 33.5) | 25.0 (13.9 to 40.0) | 15.4 (6.9 to 29.9) | 16.1 (8.1 to 29.7) | 13.0 (4.9 to 29.6) | 12.5 (4.7 to 28.2) | 15.4 (6.9 to 29.9) |
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Change at Week 1 | -0.9 ± 0.22 | -0.7 ± 0.22 | -0.6 ± 0.22 | -0.9 ± 0.22 | -0.8 ± 0.22 | -0.5 ± 0.19 | -0.7 ± 0.23 | -0.7 ± 0.22 | -0.8 ± 0.22 |
| Change at Week 2 | -1.4 ± 0.26 | -0.7 ± 0.26 | -0.9 ± 0.27 | -1.4 ± 0.26 | -1.3 ± 0.26 | -0.8 ± 0.25 | -1.4 ± 0.29 | -1.6 ± 0.29 | -1.7 ± 0.29 |
| Change at Week 4 | -1.4 ± 0.31 | -1.2 ± 0.31 | -1.2 ± 0.33 | -1.4 ± 0.31 | -1.6 ± 0.31 | -1.0 ± 0.35 | -2.3 ± 0.42 | -1.7 ± 0.41 | -2.2 ± 0.41 |
| Change at Week 6 | -1.5 ± 0.35 | -1.4 ± 0.35 | -1.2 ± 0.37 | -1.6 ± 0.35 | -2.4 ± 0.36 | -1.2 ± 0.37 | -2.5 ± 0.45 | -2.1 ± 0.44 | -2.1 ± 0.43 |
| Change at Week 8 | -1.6 ± 0.39 | -1.9 ± 0.39 | -0.9 ± 0.41 | -2.1 ± 0.39 | -2.3 ± 0.40 | -1.3 ± 0.42 | -2.4 ± 0.50 | -2.3 ± 0.48 | -2.5 ± 0.48 |
| Change at Week 10 | -1.6 ± 0.41 | -2.1 ± 0.40 | -1.6 ± 0.42 | -2.3 ± 0.40 | -2.4 ± 0.41 | -1.1 ± 0.46 | -2.4 ± 0.55 | -2.4 ± 0.53 | -2.4 ± 0.53 |
| Change at Week 12 | -1.4 ± 0.49 | -2.1 ± 0.48 | -1.2 ± 0.51 | -2.2 ± 0.48 | -2.4 ± 0.49 | -0.9 ± 0.51 | -2.5 ± 0.62 | -2.5 ± 0.59 | -2.3 ± 0.59 |
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6.12 ± 2.870 | 7.19 ± 3.370 | 6.46 ± 2.932 | 6.63 ± 3.468 | 6.83 ± 3.137 | 6.08 ± 2.558 | 7.07 ± 3.579 | 5.80 ± 2.765 | 7.94 ± 4.071 |
| Change at Week 14 | -0.83 ± 2.379 | -2.24 ± 2.945 | -0.72 ± 4.107 | -1.81 ± 3.228 | -1.87 ± 2.942 | -0.82 ± 3.581 | -1.04 ± 3.732 | -2.06 ± 3.343 | -1.19 ± 3.323 |
| Change at Week 16 | -0.46 ± 2.603 | -2.06 ± 3.252 | -0.78 ± 4.223 | -2.10 ± 3.666 | -1.68 ± 3.255 | -0.67 ± 4.008 | -0.71 ± 3.455 | -1.75 ± 3.887 | -1.03 ± 3.351 |
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
| Percent change | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Change at Week 1 | -15.5 ± 3.62 | -12.9 ± 3.57 | -8.2 ± 3.56 | -10.4 ± 3.49 | -13.0 ± 3.51 | -7.4 ± 3.10 | -9.0 ± 3.64 | -13.7 ± 3.58 | -13.5 ± 3.52 |
| Change at Week 2 | -21.6 ± 4.25 | -12.4 ± 4.10 | -12.6 ± 4.34 | -17.9 ± 4.13 | -19.8 ± 4.14 | -11.7 ± 3.99 | -20.7 ± 4.60 | -23.3 ± 4.68 | -24.7 ± 4.58 |
| Change at Week 4 | -24.1 ± 4.69 | -20.5 ± 4.65 | -15.6 ± 4.90 | -17.6 ± 4.59 | -25.1 ± 4.61 | -13.2 ± 5.69 | -33.9 ± 6.85 | -24.1 ± 6.66 | -29.2 ± 6.64 |
| Change at Week 6 | -23.7 ± 5.88 | -20.3 ± 5.83 | -18.4 ± 6.18 | -21.8 ± 5.83 | -36.0 ± 5.92 | -17.8 ± 6.10 | -36.6 ± 7.31 | -31.2 ± 7.12 | -27.5 ± 7.08 |
| Change at Week 8 | -25.3 ± 6.48 | -25.6 ± 6.44 | -14.3 ± 6.78 | -30.5 ± 6.41 | -35.9 ± 6.57 | -18.1 ± 6.70 | -35.2 ± 8.07 | -32.4 ± 7.76 | -34.3 ± 7.76 |
| Change at Week 10 | -26.8 ± 6.42 | -27.6 ± 6.34 | -22.9 ± 6.73 | -35.3 ± 6.36 | -36.1 ± 6.48 | -12.5 ± 7.62 | -33.4 ± 9.12 | -35.1 ± 8.75 | -34.6 ± 8.77 |
| Change at Week 12 | -20.0 ± 7.36 | -29.1 ± 7.30 | -18.5 ± 7.70 | -33.7 ± 7.30 | -39.0 ± 7.47 | -9.6 ± 8.61 | -34.1 ± 10.35 | -35.7 ± 9.84 | -33.7 ± 9.88 |
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
| Percent change | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6.12 ± 2.870 | 7.19 ± 3.370 | 6.46 ± 2.932 | 6.63 ± 3.468 | 6.83 ± 3.137 | 6.08 ± 2.558 | 7.07 ± 3.579 | 5.80 ± 2.765 | 7.94 ± 4.071 |
| Change at Week 14 | -12.76 ± 49.660 | -25.94 ± 40.339 | -8.58 ± 59.407 | -23.14 ± 47.501 | -30.07 ± 40.222 | -5.74 ± 74.846 | -14.18 ± 58.599 | -27.56 ± 45.370 | -19.74 ± 49.727 |
| Change at Week 16 | -4.72 ± 56.401 | -23.01 ± 44.766 | -9.00 ± 60.088 | -29.24 ± 52.608 | -27.17 ± 41.153 | -3.75 ± 83.415 | -9.99 ± 60.306 | -24.09 ± 48.685 | -21.12 ± 52.521 |
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 4.6 ± 0.31 | 4.4 ± 0.30 | 4.5 ± 0.31 | 4.1 ± 0.33 | 4.5 ± 0.29 | 4.9 ± 0.28 | 4.8 ± 0.32 | 4.4 ± 0.32 | 5.4 ± 0.34 |
| Week 1 | 4.1 ± 0.31 | 3.9 ± 0.30 | 3.6 ± 0.31 | 3.5 ± 0.33 | 3.6 ± 0.30 | 4.0 ± 0.28 | 3.8 ± 0.32 | 3.4 ± 0.32 | 3.7 ± 0.35 |
| Week 2 | 3.6 ± 0.31 | 3.5 ± 0.31 | 3.3 ± 0.31 | 3.2 ± 0.33 | 3.5 ± 0.30 | 3.5 ± 0.28 | 3.6 ± 0.32 | 2.9 ± 0.32 | 3.4 ± 0.35 |
| Week 4 | 3.5 ± 0.32 | 3.7 ± 0.32 | 3.2 ± 0.33 | 3.2 ± 0.34 | 3.2 ± 0.30 | 3.4 ± 0.29 | 3.0 ± 0.34 | 3.0 ± 0.34 | 3.4 ± 0.36 |
| Week 6 | 3.5 ± 0.32 | 4.0 ± 0.32 | 3.5 ± 0.34 | 3.2 ± 0.34 | 2.9 ± 0.32 | 3.6 ± 0.31 | 2.8 ± 0.35 | 3.0 ± 0.35 | 2.9 ± 0.38 |
| Week 8 | 3.1 ± 0.32 | 3.4 ± 0.32 | 3.2 ± 0.33 | 3.1 ± 0.34 | 2.8 ± 0.32 | 3.3 ± 0.32 | 2.7 ± 0.37 | 2.9 ± 0.35 | 2.7 ± 0.38 |
| Week 10 | 3.3 ± 0.33 | 3.0 ± 0.33 | 3.0 ± 0.34 | 3.1 ± 0.35 | 2.3 ± 0.32 | 4.1 ± 0.33 | 2.8 ± 0.36 | 2.9 ± 0.35 | 3.6 ± 0.39 |
| Week 12 | 3.4 ± 0.33 | 3.1 ± 0.33 | 3.1 ± 0.33 | 3.0 ± 0.35 | 2.6 ± 0.32 | 4.0 ± 0.32 | 2.7 ± 0.37 | 3.0 ± 0.35 | 3.2 ± 0.40 |
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Week 14 | 5.2 ± 3.02 | 2.6 ± 2.52 | 2.8 ± 2.38 | 2.4 ± 2.39 | 3.2 ± 2.38 | 4.0 ± 2.77 | 3.5 ± 2.89 | 2.8 ± 2.57 | 5.5 ± 2.81 |
| Week 16 | 4.9 ± 2.93 | 3.2 ± 2.75 | 3.1 ± 2.63 | 2.5 ± 2.45 | 3.2 ± 2.42 | 3.8 ± 2.69 | 3.4 ± 2.77 | 3.5 ± 2.91 | 5.8 ± 2.76 |
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Change at Week 1 | -0.4 ± 0.23 | -0.6 ± 0.23 | -0.9 ± 0.23 | -0.9 ± 0.25 | -0.9 ± 0.22 | -0.9 ± 0.24 | -1.0 ± 0.27 | -1.4 ± 0.28 | -1.2 ± 0.30 |
| Change at Week 2 | -0.9 ± 0.28 | -0.9 ± 0.27 | -1.1 ± 0.28 | -1.2 ± 0.30 | -1.0 ± 0.27 | -1.3 ± 0.25 | -1.3 ± 0.29 | -1.9 ± 0.30 | -1.5 ± 0.32 |
| Change at Week 4 | -1.0 ± 0.33 | -0.8 ± 0.33 | -1.0 ± 0.34 | -1.2 ± 0.36 | -1.2 ± 0.32 | -1.3 ± 0.32 | -1.7 ± 0.38 | -1.7 ± 0.38 | -1.6 ± 0.41 |
| Change at Week 6 | -0.9 ± 0.36 | -0.4 ± 0.36 | -1.0 ± 0.38 | -1.2 ± 0.39 | -1.6 ± 0.36 | -1.1 ± 0.31 | -1.9 ± 0.36 | -1.8 ± 0.36 | -2.1 ± 0.39 |
| Change at Week 8 | -1.4 ± 0.38 | -1.1 ± 0.38 | -1.2 ± 0.39 | -1.3 ± 0.41 | -1.6 ± 0.38 | -1.2 ± 0.38 | -2.2 ± 0.44 | -1.8 ± 0.43 | -2.2 ± 0.46 |
| Change at Week 10 | -1.1 ± 0.43 | -1.4 ± 0.44 | -1.3 ± 0.45 | -1.2 ± 0.46 | -2.1 ± 0.42 | -0.5 ± 0.39 | -2.1 ± 0.44 | -1.9 ± 0.42 | -1.2 ± 0.47 |
| Change at Week 12 | -1.0 ± 0.42 | -1.3 ± 0.43 | -1.2 ± 0.44 | -1.3 ± 0.45 | -1.8 ± 0.42 | -0.6 ± 0.41 | -2.3 ± 0.47 | -1.8 ± 0.44 | -1.5 ± 0.49 |
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Change at Week 14 | -0.4 ± 3.18 | -1.4 ± 1.64 | -1.8 ± 3.16 | -1.2 ± 2.52 | -1.1 ± 2.38 | -1.0 ± 2.93 | -1.1 ± 2.57 | -1.3 ± 2.31 | -0.1 ± 4.18 |
| Change at Week 16 | -0.6 ± 2.97 | -0.9 ± 1.82 | -1.2 ± 3.21 | -0.7 ± 2.02 | -1.0 ± 2.52 | -0.9 ± 2.99 | -1.0 ± 2.29 | -0.9 ± 2.25 | 0.4 ± 3.54 |
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 14.2 ± 5.96 | 12.3 ± 7.18 | 13.2 ± 6.55 | 10.3 ± 5.00 | 12.3 ± 6.48 | 14.0 ± 6.60 | 13.0 ± 6.09 | 10.1 ± 5.70 | 16.6 ± 7.01 |
| Week 1 | 11.2 ± 4.17 | 9.1 ± 5.85 | 9.7 ± 5.29 | 7.8 ± 4.23 | 8.9 ± 6.10 | 9.6 ± 4.86 | 9.5 ± 4.86 | 7.0 ± 4.96 | 9.7 ± 4.24 |
| Week 2 | 10.3 ± 4.57 | 8.4 ± 5.07 | 9.2 ± 5.03 | 7.1 ± 4.01 | 8.2 ± 5.17 | 8.4 ± 4.52 | 9.1 ± 5.47 | 6.0 ± 4.30 | 8.4 ± 3.62 |
| Week 4 | 11.6 ± 5.81 | 9.2 ± 5.25 | 9.9 ± 5.29 | 7.3 ± 3.97 | 8.1 ± 4.89 | 9.6 ± 6.96 | 7.9 ± 5.57 | 6.6 ± 4.60 | 8.3 ± 3.99 |
| Week 6 | 11.6 ± 6.61 | 9.7 ± 5.79 | 10.4 ± 6.20 | 6.2 ± 3.79 | 7.6 ± 4.69 | 8.8 ± 5.96 | 6.1 ± 3.23 | 6.9 ± 5.06 | 8.2 ± 4.23 |
| Week 8 | 11.3 ± 5.82 | 8.7 ± 5.87 | 9.7 ± 6.62 | 6.1 ± 3.73 | 7.0 ± 4.61 | 8.4 ± 5.46 | 7.2 ± 4.75 | 7.5 ± 4.92 | 8.0 ± 4.68 |
| Week 10 | 11.7 ± 7.09 | 8.0 ± 6.29 | 9.5 ± 5.89 | 6.5 ± 3.66 | 6.4 ± 4.87 | 7.8 ± 4.92 | 6.7 ± 3.13 | 6.7 ± 4.60 | 9.5 ± 4.97 |
| Week 12 | 11.7 ± 7.40 | 7.8 ± 6.41 | 9.7 ± 6.45 | 5.9 ± 3.38 | 6.2 ± 4.69 | 8.0 ± 5.13 | 6.1 ± 3.67 | 6.8 ± 5.14 | 8.3 ± 4.79 |
| Week 14 | 14.3 ± 8.09 | 8.1 ± 6.37 | 8.9 ± 6.09 | 6.8 ± 5.00 | 9.2 ± 6.12 | 10.4 ± 5.98 | 11.2 ± 7.54 | 8.5 ± 6.04 | 11.5 ± 5.26 |
| Week 16 | 14.0 ± 7.60 | 8.6 ± 6.30 | 9.8 ± 5.47 | 7.4 ± 5.03 | 8.9 ± 6.77 | 10.4 ± 6.18 | 11.5 ± 7.20 | 10.2 ± 6.82 | 11.9 ± 7.33 |
| ET | 7.7 ± 4.04 | 13.0 ± 1.00 | 12.8 ± 6.76 | 13.3 ± 7.02 | 15.8 ± 11.73 | 18.7 ± 10.23 | 18.0 ± 11.87 | 11.0 ± 8.21 | 19.3 ± 8.14 |
| ET follow-up visit 1 | 7.0 ± 4.24 | 9.0 ± NA | 6.0 ± 4.24 | 4.0 ± NA | 2.0 ± NA | 19.0 ± 15.56 | 8.5 ± 2.12 | 4.0 ± NA | 7.0 ± NA |
| ET follow-up visit 2 | 8.0 ± 5.66 | 7.0 ± NA | 4.5 ± 2.12 | 4.0 ± NA | 22.5 ± 9.19 | 17.8 ± 11.41 | 4.0 ± 0.00 | 13.0 ± 13.74 | 15.5 ± 10.61 |
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
| Unit on a scale | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Change at Week 1 | -3.3 ± 4.94 | -2.8 ± 3.35 | -3.0 ± 3.84 | -2.6 ± 2.95 | -3.4 ± 4.17 | -3.9 ± 5.00 | -3.7 ± 3.49 | -3.4 ± 3.18 | -6.6 ± 4.80 |
| Change at Week 2 | -4.0 ± 5.46 | -3.9 ± 4.91 | -4.1 ± 4.36 | -3.1 ± 3.63 | -3.8 ± 4.62 | -5.1 ± 5.85 | -4.2 ± 3.91 | -4.3 ± 4.12 | -7.8 ± 5.37 |
| Change at Week 4 | -3.0 ± 6.33 | -3.4 ± 5.09 | -3.5 ± 5.12 | -2.6 ± 3.91 | -4.1 ± 4.55 | -3.9 ± 6.50 | -4.6 ± 5.44 | -3.7 ± 4.57 | -6.5 ± 5.44 |
| Change at Week 6 | -3.5 ± 7.09 | -3.1 ± 5.30 | -2.0 ± 6.20 | -3.5 ± 5.22 | -4.0 ± 4.64 | -5.1 ± 7.40 | -6.3 ± 5.05 | -3.4 ± 4.60 | -6.5 ± 5.75 |
| Change at Week 8 | -4.1 ± 7.20 | -3.5 ± 4.60 | -3.2 ± 6.56 | -3.7 ± 5.01 | -4.1 ± 5.01 | -5.2 ± 8.12 | -5.8 ± 5.35 | -3.2 ± 4.90 | -7.0 ± 6.64 |
| Change at Week 10 | -4.0 ± 7.57 | -4.0 ± 4.90 | -3.4 ± 6.24 | -3.3 ± 6.12 | -5.3 ± 5.69 | -5.5 ± 8.08 | -5.1 ± 5.12 | -3.9 ± 4.82 | -5.8 ± 7.62 |
| Change at Week 12 | -3.8 ± 7.74 | -4.1 ± 4.98 | -3.2 ± 5.63 | -3.7 ± 6.13 | -5.2 ± 6.04 | -5.0 ± 8.15 | -5.2 ± 4.82 | -3.7 ± 5.67 | -6.6 ± 7.82 |
| Change at Week 14 | -0.7 ± 7.86 | -2.9 ± 4.68 | -4.4 ± 7.49 | -3.1 ± 6.87 | -2.2 ± 5.49 | -3.5 ± 7.87 | -1.4 ± 5.53 | -2.3 ± 4.98 | -2.9 ± 7.98 |
| Change at Week 16 | -0.9 ± 7.61 | -2.4 ± 5.02 | -3.2 ± 6.37 | -2.4 ± 7.27 | -2.1 ± 6.05 | -2.6 ± 7.12 | -0.8 ± 4.29 | -0.8 ± 5.28 | -2.7 ± 8.40 |
| Change at ET | -2.7 ± 2.52 | 0.7 ± 6.11 | -1.0 ± 8.29 | 0.3 ± 2.08 | -1.3 ± 6.85 | 0.7 ± 5.16 | 1.8 ± 7.40 | -4.0 ± 3.00 | -5.0 ± 1.41 |
| Change at ET Follow-up Visit 1 | -2.5 ± 0.71 | -9.0 ± NA | -5.0 ± 7.07 | -4.0 ± NA | -3.0 ± NA | 2.0 ± 9.90 | -2.5 ± 0.71 | -7.0 ± NA | -9.0 ± NA |
| Change at ET Follow-up Visit 2 | -1.5 ± 2.12 | -11.0 ± NA | -6.5 ± 4.95 | -4.0 ± NA | 6.5 ± 9.19 | 0.8 ± 7.14 | -11.0 ± 4.24 | -0.3 ± 8.26 | -1.0 ± 9.90 |
PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.
| Percentage of participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | 2.8 (0.3 to 11.6) | 2.7 (0.3 to 11.2) | 2.7 (0.3 to 11.2) | 0 (0.0 to 7.5) | 0 (0.0 to 7.3) | 0 (0.0 to 5.5) | 0 (0.0 to 7.5) | 5.7 (1.5 to 16.4) | 5.3 (1.4 to 15.0) |
| Week 2 | 2.8 (0.3 to 11.6) | 0 (0.0 to 7.3) | 0 (0.0 to 7.3) | 2.8 (0.3 to 11.6) | 2.7 (0.3 to 11.2) | 2.0 (0.2 to 8.4) | 0 (0.0 to 7.5) | 5.7 (1.5 to 16.4) | 10.5 (4.7 to 21.6) |
| Week 4 | 5.6 (1.5 to 15.9) | 5.4 (1.4 to 15.5) | 0 (0.0 to 7.3) | 5.6 (1.5 to 15.9) | 5.4 (1.4 to 15.5) | 8.2 (3.6 to 16.5) | 8.3 (3.1 to 18.9) | 11.4 (5.1 to 23.6) | 21.1 (10.9 to 33.3) |
| Week 6 | 8.3 (3.1 to 18.9) | 5.4 (1.4 to 15.5) | 2.7 (0.3 to 11.2) | 8.3 (3.1 to 18.9) | 13.5 (6.7 to 24.8) | 8.2 (3.6 to 16.5) | 8.3 (3.1 to 18.9) | 5.7 (1.5 to 16.4) | 13.2 (6.5 to 24.3) |
| Week 8 | 11.1 (4.9 to 22.9) | 5.4 (1.4 to 15.5) | 5.4 (1.4 to 15.5) | 2.8 (0.3 to 11.6) | 10.8 (4.8 to 22.2) | 6.1 (2.3 to 14.8) | 13.9 (6.9 to 25.4) | 5.7 (1.5 to 16.4) | 18.4 (10.1 to 30.9) |
| Week 10 | 8.3 (3.1 to 18.9) | 5.4 (1.4 to 15.5) | 8.1 (3.0 to 18.5) | 8.3 (3.1 to 18.9) | 16.2 (7.3 to 29.3) | 16.3 (8.4 to 27.1) | 16.7 (7.5 to 30.2) | 8.6 (3.2 to 19.3) | 13.2 (6.5 to 24.3) |
| Week 14 | 2.8 (0.3 to 11.6) | 13.5 (6.7 to 24.8) | 5.6 (1.5 to 15.9) | 8.6 (3.2 to 19.3) | 13.5 (6.7 to 24.8) | 6.3 (2.3 to 15.1) | 8.8 (3.3 to 19.7) | 11.8 (5.2 to 24.3) | 8.1 (3.0 to 18.5) |
| Week 16 | 5.6 (1.5 to 15.9) | 11.4 (5.1 to 23.6) | 8.6 (3.2 to 19.3) | 14.3 (7.1 to 26.0) | 16.2 (7.3 to 29.3) | 8.2 (3.6 to 16.5) | 14.7 (7.3 to 26.9) | 11.8 (5.2 to 24.3) | 16.2 (7.3 to 29.3) |
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
| Percentage of participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | 5.7 (1.5 to 16.4) | 19.4 (10.7 to 32.8) | 11.8 (5.2 to 24.3) | 22.2 (11.6 to 35.3) | 13.5 (6.7 to 24.8) | 19.1 (11.2 to 30.3) | 11.4 (5.1 to 23.6) | 26.5 (15.9 to 40.5) | 24.1 (13.4 to 38.5) |
| Week 2 | 8.6 (3.2 to 19.3) | 22.2 (11.6 to 35.3) | 18.2 (8.2 to 31.3) | 34.3 (22.0 to 47.8) | 31.4 (19.3 to 44.8) | 20.8 (11.8 to 31.5) | 25.7 (15.4 to 39.2) | 31.4 (19.3 to 44.8) | 32.3 (18.7 to 48.2) |
| Week 4 | 15.6 (7.8 to 28.7) | 29.0 (17.6 to 45.0) | 29.6 (15.7 to 45.3) | 48.5 (34.4 to 63.9) | 38.2 (24.3 to 53.8) | 26.1 (15.8 to 37.7) | 31.0 (18.9 to 46.3) | 51.6 (36.8 to 67.3) | 35.5 (21.3 to 51.8) |
| Week 6 | 18.8 (8.5 to 32.0) | 26.7 (14.0 to 41.6) | 32.0 (17.0 to 50.0) | 54.8 (39.9 to 70.3) | 42.9 (28.4 to 60.0) | 31.6 (19.9 to 45.9) | 66.7 (50.0 to 79.6) | 48.1 (32.6 to 65.3) | 33.3 (20.4 to 50.0) |
| Week 8 | 23.3 (12.9 to 37.6) | 35.5 (21.3 to 51.8) | 46.2 (29.9 to 63.8) | 67.7 (51.8 to 81.3) | 50.0 (34.2 to 65.8) | 41.7 (29.0 to 56.0) | 62.5 (44.7 to 77.9) | 35.7 (20.8 to 52.7) | 59.3 (41.7 to 75.2) |
| Week 10 | 31.0 (18.9 to 46.3) | 42.9 (28.4 to 60.0) | 40.0 (24.6 to 58.3) | 62.1 (46.3 to 77.1) | 64.3 (47.3 to 79.2) | 45.2 (29.7 to 60.1) | 50.0 (31.9 to 68.1) | 46.4 (31.0 to 63.4) | 33.3 (17.8 to 52.1) |
| Week 12 | 24.1 (13.4 to 38.5) | 51.7 (35.2 to 68.0) | 50.0 (34.2 to 65.8) | 62.1 (46.3 to 77.1) | 55.6 (38.2 to 70.9) | 35.5 (21.3 to 51.8) | 56.5 (38.1 to 72.7) | 46.4 (31.0 to 63.4) | 36.0 (21.4 to 54.4) |
| Week 14 | 7.1 (1.9 to 20.1) | 44.0 (27.0 to 61.1) | 45.8 (28.2 to 63.0) | 54.2 (37.0 to 71.8) | 37.0 (22.1 to 54.7) | 25.9 (14.5 to 41.7) | 30.4 (17.3 to 47.9) | 36.0 (21.4 to 54.4) | 17.4 (7.8 to 33.5) |
| Week 16 | 7.4 (2.0 to 20.4) | 44.4 (29.1 to 61.8) | 30.4 (17.3 to 47.9) | 54.2 (37.0 to 71.8) | 52.0 (36.0 to 69.3) | 36.7 (22.1 to 52.4) | 18.2 (8.2 to 35.3) | 22.7 (11.5 to 39.5) | 31.6 (15.1 to 53.0) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent AEs | 17 | 16 | 14 | 17 | 14 | 20 | 13 | 18 | 12 |
| Treatment-emergent SAEs | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 0 |
| Treatment-related AEs | 1 | 0 | 2 | 2 | 3 | 2 | 3 | 3 | 1 |
| Treatment-related SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event).
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Mild | 12 | 9 | 11 | 11 | 7 | 8 | 7 | 11 | 6 |
| Moderate | 5 | 7 | 3 | 5 | 7 | 11 | 6 | 5 | 6 |
| Severe | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued From Study Due to Adverse Events | 1 | 1 | 3 | 0 | 2 | 1 | 1 | 2 | 1 |
Bilirubin: greater than (\>) 1.5\* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: \>2.5\*ULN; creatinine, cystatin C: \>1.3\*ULN; creatine kinase: \>2.0\*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (\<) 60 milliliter (mL)/minute (min)/1.73 meter(m)\^2, greater than or equal to (\>=) 30% decrease from baseline; GFR: \<60 mL/min/1.73m\^2.
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 7 | 6 | 11 | 7 | 5 | 12 | 5 | 6 | 15 |
Following were ECG criteria used for categorical summary:1) PR interval: percentage change \>=25/50%, QRS interval: value \>140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec \< value less than equal to (\<=) 480 and 30 \< change \<=60.
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Post-baseline to Week 6: QRS interval (>=140 msec) | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Post-baseline to Week 6: QTcF interval (30< Change <=60) | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Post-baseline to Week 12: QRS interval (>=140 msec) | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Post-baseline to Week 12: QTcF interval (450< Value <=480) | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
| Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 |
Following were the vital signs criteria: 1) Pulse rate: value \<40 beats per min (bpm), value \>120 bpm; 2) Sitting diastolic blood pressure (DBP): value \<50 mmHg; change \>=20 mmHg increase; change \>=20 mmHg decrease; 3) Sitting systolic blood pressure (SBP): value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease; 4) Supine DBP: value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; 5) Supine SBP: value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease.
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Pulse rate < 40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate >120 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting DBP (<50 mmHg) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting DBP (>=20 mmHg increase) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting DBP (>=20 mmHg decrease) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting SBP (<90 mmHg) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting SBP (>= 30 mmHg increase) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sitting SBP (>=30 mmHg decrease) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Supine DBP (<50 mmHg) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine DBP (>= 20mmHg increase) | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 2 |
| Supine DBP (>=20 mmHg decrease) | 0 | 2 | 0 | 0 | 1 | 4 | 0 | 0 | 0 |
| Supine SBP (<90 mmHg) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine SBP (>=30 mmHg increase) | 1 | 0 | 1 | 2 | 0 | 2 | 0 | 2 | 1 |
| Supine SBP (>= 30 mmHg decrease) | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]).
| Participants | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Day1 — None | 36 | 37 | 36 | 36 | 36 | 48 | 35 | 36 | 37 |
| Day1 — Mild | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Day1 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Day1 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day1 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day1 — Missing | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Week 1 — None | 32 | 35 | 32 | 34 | 35 | 44 | 32 | 32 | 35 |
| Week 1 — Mild | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 2 | 1 |
| Week 1 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 1 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 1 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 1 — Missing | 3 | 1 | 4 | 0 | 2 | 4 | 4 | 2 | 1 |
| Week 2 — None | 33 | 35 | 30 | 34 | 35 | 45 | 34 | 35 | 33 |
| Week 2 — Mild | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 2 |
| Week 2 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Week 2 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 — Missing | 1 | 1 | 5 | 1 | 1 | 2 | 0 | 1 | 2 |
| Week 4 — None | 34 | 32 | 29 | 32 | 34 | 44 | 30 | 32 | 30 |
| Week 4 — Mild | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 3 |
| Week 4 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 — Missing | 0 | 2 | 5 | 1 | 1 | 2 | 2 | 3 | 2 |
| Week 6 — None | 32 | 31 | 26 | 30 | 27 | 37 | 28 | 31 | 30 |
| Week 6 — Mild | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Week 6 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 — Missing | 1 | 1 | 5 | 4 | 3 | 7 | 3 | 4 | 2 |
| Week 8 — None | 29 | 30 | 27 | 30 | 26 | 34 | 26 | 30 | 28 |
| Week 8 — Mild | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Week 8 — Moderate | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 8 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 — Missing | 2 | 2 | 6 | 4 | 4 | 6 | 3 | 4 | 4 |
| Week 10 — None | 29 | 30 | 24 | 29 | 27 | 34 | 24 | 27 | 26 |
| Week 10 — Mild | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Week 10 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 — Missing | 3 | 1 | 7 | 3 | 3 | 6 | 4 | 7 | 4 |
| Week 12 — None | 33 | 32 | 30 | 31 | 30 | 43 | 30 | 32 | 29 |
| Week 12 — Mild | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Week 12 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Week 12 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 — Missing | 3 | 4 | 6 | 3 | 4 | 3 | 3 | 3 | 5 |
| Week 14 — None | 31 | 27 | 24 | 29 | 30 | 34 | 26 | 26 | 28 |
| Week 14 — Mild | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 14 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 14 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 14 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 14 — Missing | 5 | 7 | 10 | 5 | 4 | 11 | 8 | 9 | 5 |
| Week 16 — None | 31 | 28 | 26 | 28 | 28 | 35 | 26 | 28 | 26 |
| Week 16 — Mild | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 16 — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 — Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 — Very severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16 — Missing | 4 | 7 | 9 | 7 | 4 | 10 | 8 | 6 | 7 |
Collected over Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Once Daily (QD) | 0/37 (0%) | 1/37 (2.7%) | 7/37 (18.9%) |
| PF-06700841 0.1% QD | 0/37 (0%) | 0/37 (0%) | 7/37 (18.9%) |
| PF-06700841 0.3% QD | 0/37 (0%) | 0/37 (0%) | 7/37 (18.9%) |
| PF-06700841 1.0% QD | 0/36 (0%) | 1/36 (2.8%) | 9/36 (25%) |
| PF-06700841 3.0% QD | 0/37 (0%) | 0/37 (0%) | 8/37 (21.6%) |
| Pooled Vehicle BID | 1/49 (2%) | 1/49 (2%) | 10/49 (20.4%) |
| PF-06700841 0.3% BID | 0/36 (0%) | 1/36 (2.8%) | 4/36 (11.1%) |
| PF-06700841 1.0% BID | 0/36 (0%) | 2/36 (5.6%) | 10/36 (27.8%) |
| PF-06700841 3.0% BID | 0/38 (0%) | 0/38 (0%) | 2/38 (5.3%) |
| Event | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| Thrombophlebitis septicInfections and infestations | 0/37 | 0/37 | 0/37 | 0/36 | 0/37 | 0/49 | 0/36 | 1/36 | 0/38 |
| Urinary tract infectionInfections and infestations | 0/37 | 0/37 | 0/37 | 0/36 | 0/37 | 0/49 | 0/36 | 1/36 | 0/38 |
| Aspiration bursaInvestigations | 0/37 | 0/37 | 0/37 | 1/36 | 0/37 | 0/49 | 0/36 | 0/36 | 0/38 |
| LethargyNervous system disorders | 0/37 | 0/37 | 0/37 | 0/36 | 0/37 | 0/49 | 0/36 | 1/36 | 0/38 |
| DepressionPsychiatric disorders | 0/37 | 0/37 | 0/37 | 0/36 | 0/37 | 0/49 | 1/36 | 0/36 | 0/38 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/37 | 0/37 | 0/37 | 0/36 | 0/37 | 0/49 | 0/36 | 1/36 | 0/38 |
| BacteraemiaInfections and infestations | 1/37 | 0/37 | 0/37 | 0/36 | 0/37 | 0/49 | 0/36 | 0/36 | 0/38 |
| Cardiopulmonary failureCardiac disorders | 0/37 | 0/37 | 0/37 | 0/36 | 0/37 | 1/49 | 0/36 | 0/36 | 0/38 |
| Event | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/37 | 3/37 | 1/37 | 6/36 | 3/37 | 3/49 | 1/36 | 7/36 | 0/38 |
| Blood creatine phosphokinase increasedInvestigations | 1/37 | 0/37 | 0/37 | 2/36 | 1/37 | 0/49 | 0/36 | 0/36 | 0/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/37 | 0/37 | 2/37 | 1/36 | 0/37 | 2/49 | 2/36 | 2/36 | 0/38 |
| PruritusSkin and subcutaneous tissue disorders | 1/37 | 0/37 | 1/37 | 0/36 | 0/37 | 1/49 | 0/36 | 2/36 | 1/38 |
| HypertensionVascular disorders | 0/37 | 0/37 | 1/37 | 0/36 | 2/37 | 2/49 | 0/36 | 2/36 | 1/38 |
| RhinitisInfections and infestations | 0/37 | 1/37 | 2/37 | 0/36 | 0/37 | 1/49 | 0/36 | 0/36 | 0/38 |
| Upper respiratory tract infectionInfections and infestations | 1/37 | 2/37 | 1/37 | 0/36 | 2/37 | 2/49 | 1/36 | 0/36 | 1/38 |
| HeadacheNervous system disorders | 0/37 | 2/37 | 0/37 | 0/36 | 0/37 | 0/49 | 1/36 | 0/36 | 0/38 |
Analysis population included participants who were randomly assigned to PF-06700841 and applied at least 1 dose of PF-06700841.
| Age, Continuous(Years) | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 48.6 ± 15.83 | 51.8 ± 12.49 | 51.4 ± 12.26 | 49.4 ± 15.30 | 48.4 ± 12.37 | 50.9 ± 12.85 | 48.2 ± 13.58 | 50.9 ± 16.45 | 48.9 ± 12.93 | 49.9 ± 13.72 |
| Sex: Female, Male(Participants) | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 10 | 7 | 6 | 13 | 18 | 11 | 11 | 14 | 102 |
| Male | 25 | 27 | 30 | 30 | 24 | 31 | 25 | 25 | 24 | 241 |
| Ethnicity (NIH/OMB)(Participants) | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 4 | 1 | 2 | 8 | 3 | 3 | 7 | 35 |
| Not Hispanic or Latino | 32 | 35 | 33 | 35 | 35 | 39 | 33 | 33 | 31 | 306 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Asian | 6 | 4 | 6 | 6 | 4 | 3 | 6 | 3 | 2 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 2 | 7 |
| White | 30 | 33 | 28 | 30 | 32 | 45 | 30 | 31 | 34 | 293 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2019 to primary completion in Apr 2021, 24 months.
Results were first posted in Jun 2022, 1 year 2 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 24 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841